Assertio Holdings announces results of Rolvedon injection study

Assertio Holdings (ASRT) announced yesterday results of a clinical trial investigating the utility of Rolvedon injection when dosed the same day of chemotherapy for patients with early stage breast cancer, ESBC. The results were presented as part of the San Antonio Breast Cancer Symposium by the American Association of Cancer Research and the University of Texas Health Science Center at San Antonio. In this open-label, single-arm study, conducted across 13 sites in the US, individuals received Rolvedon 30 minutes post chemotherapy for ESBC. Rolvedon demonstrated 1.8 days to neutrophil count recovery and a febrile neutropenia rate of 2%. Zero patients required the need for hospitalization and/or intervention for febrile neutropenia. No new safety signals were identified.